Micro-Caps — page 12
Standard BioTools Drops 2026 Revenue Outlook Amid Treeline Merger
Second-quarter revenue was $20.1 million as the company said it is on track to close the Treeline Biosciences combination before year-end.
Kaltura Restores Year-Over-Year Revenue Growth
Second-quarter revenue was $46.9 million, up 5% from a year earlier, after a 5% decline in the first quarter, and the company said it beat the high end of its guidance.
Inspired Entertainment's Adjusted EBITDA Margin Reaches 45%
Adjusted EBITDA reached $27.1 million in the second quarter, up 14% from the prior quarter, as the company reaffirmed a 2026 target of $112 million to $118 million.
Immuneering Doses MAPKeeper 301 After ASCO Survival Data
The company reported 17.3-month median overall survival in 55 first-line pancreatic cancer patients on atebimetinib plus mGnP, with cash of $182.7 million and runway still expected into 2029.
ISG Posts Highest Quarterly Revenue Since 2023
Second-quarter revenue reached $65.5 million, up 6.4% from a year earlier, as year-over-year growth accelerated from the first quarter's 3% pace.
Holley Completes Restoration Brand Sales
Net sales rose 3.2% to $172.0 million as the company booked a $28.3 million loss on the sale of non-core assets.
Hudson Cuts 2026 Gross-Margin Target After Volume Gain
Second-quarter revenue reached $78.3 million as sales volume rose 12% and selling prices fell 6%.
FTAI Infrastructure Posts Record Rail Earnings
Railroad Adjusted EBITDA reached $42.4 million as the company booked $76.1 million of group Adjusted EBITDA and a $63.2 million impairment.
Energy Recovery's Megaproject Sales Collapse After Iran War
Second-quarter revenue fell 57% to $12.0 million as megaproject sales dropped 82% and the company posted a $3.2 million net loss.
Emergent Cuts Full-Year Outlook After Naloxone Impairment
Second-quarter revenue reached $234.3 million as medical countermeasures rose, while the company booked a $191.3 million NARCAN impairment and lowered full-year revenue guidance to $645 million to $675 million.
DHI Raises Dice Margin Outlook, Reaffirms Revenue Guidance
ClearanceJobs bookings rose 24% to $14.3 million as the company lifted Dice's full-year Adjusted EBITDA margin target to 24% from 22%.
Coherus Oncology Restores LOQTORZI Growth After Weather-Weighed Quarter
LOQTORZI net revenue reached $13.6 million in the second quarter, up 15% from $11.8 million in the first quarter.
BioAge Doses First Patient in BGE-102 Phase 2 Trial
The company said QUELL-CV topline data are expected in the second half of 2026, with cash of about $381.3 million funding operations through 2029.
Biodesix Test Volume Growth Accelerates
Second-quarter revenue was $26.9 million, up 34%, as diagnostic test volumes rose 38% to 20,900.
Alto Extends Profit Streak to a Fourth Quarter
Second-quarter net income attributable to common stockholders was $11.4 million, or $0.15 a share, after a $1.9 million gross loss a year earlier.
Akebia Turns to a Loss as Auryxia Recedes
Vafseo net product sales reached $21.3 million in the second quarter, up 34% from the first quarter, as more than 10,500 patients were on therapy.
Intersnack Group to Buy Utz Brands in All-Cash Deal
The acquisition will take the U.S. snack manufacturer private, with Intersnack Group and the Rice and Lissette Family Entities each holding a 50% stake.
Eton Pharmaceuticals to Acquire U.S. Rights to ASN-001 From Auson
The asset purchase pairs a late-stage hemangioma candidate with Eton's existing HEMANGEOL franchise, extending a commercial infrastructure built for pediatric dermatology.
Mubadala Capital Consortium to Buy Clear Channel Outdoor for $6.2 Billion
The all-cash take-private, first struck in February at $2.43 a share, heads toward a third-quarter close after clearing a stockholder vote and a CFIUS review.
Quantum Computing: Scaling Hardware and Securing Assets
Companies are pivoting toward hybrid architectures and quantum-safe security as the industry chases the threshold of quantum advantage.
GLP-1 Shift: Branded Access and Oral Formulations Gain Ground
Virtual care providers and biotech firms are pivoting toward FDA-approved branded therapies and oral delivery systems to stabilize supply and improve patient persistence.
AI Compute Shifts Toward Modular and Co-Located Power
Infrastructure providers are pivoting to containerized data centers and direct energy asset co-location to bypass grid bottlenecks.
AI Infrastructure and Regulatory Risks Scale Across Sectors
Companies are flagging critical dependencies on a small number of cloud vendors and a fragmented global regulatory landscape.
Exagen Raises 2026 Revenue Outlook After Record Quarter
Second-quarter revenue reached a record $19.9 million as the company lifted full-year guidance to $72 million to $75 million.
USANA Swings to Loss After Hiya Goodwill Impairment
The health-products company booked a $29.1 million preliminary Hiya goodwill charge and cut fiscal 2026 sales guidance to $910 million.
Wheels Up Completes Fleet Modernization as Charter Bookings Fall
GAAP revenue was $182.0 million in the second quarter, down 4% year over year, while Adjusted EBITDAR loss narrowed 27% to $19.9 million.
Superior Group Confirms 2026 Outlook After Apparel Impairment
Adjusted earnings were $0.21 a share after a $2.6 million Healthcare Apparel tradename charge that left reported profit at $0.08 a share.
Niagen Launches NB4168 Drug Candidate and Telehealth Platform
Second-quarter net sales were $29.8 million, including $24.2 million from Tru Niagen, as the company introduced NB4168 and a Niagen Plus telehealth channel.
InfuSystem Oncology Crosses $20 Million in a Quarter
Net revenues reached $36.9 million, up 2.6% from a year earlier, and Adjusted EBITDA rose 7.6% to $8.6 million.
Horizon NAV Falls After Single-Name Unrealized Losses
Net asset value was $6.23 a share at June 30, 2026, after $38.5 million of net unrealized depreciation, or $0.59 a share.